Sign in
Taking people in United StatesPhase 2

Freezing Tumors and Immunotherapy Drugs for Advanced Melanoma

Tests freezing a growing tumor with ipilimumab and nivolumab in adults with melanoma.

Key facts

Who runs it
Massachusetts General Hospital
Where
Boston, United StatesSee the site
Trial code
Registry title
Cryoablation+Ipilimumab+Nivolumab in Melanoma
Status
Recruiting
Phase
Phase 2
People taking part
37 people, planned
Started
23 Sept 2023
Expected to end
1 Jan 2028
Type of study
Interventional
Treatments tested
  • Ipilimumab
  • Nivolumab
  • Cryoablation
Record updated
27 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with melanoma that cannot be removed by surgery and has grown after immunotherapy. They get cryoablation (freezing part of a tumor) plus ipilimumab and nivolumab.

Age
Adults over 18 years
Sex
All sexes can join.
Disease stage
Melanoma that cannot be removed by surgery and has progressed on immune checkpoint inhibitor therapy. There must be a tumor that can be frozen through the skin. There must also be another measurable tumor.
Earlier treatment
Must have had progress on immune checkpoint inhibitor therapy (such as pembrolizumab, nivolumab, nivolumab-relatimab, atezolizumab or ipilimumab). Radiation to other sites is allowed. The tumor to be frozen cannot have had radiation or other local treatment.

Main reasons for not taking part

  • Progressing on ipilimumab plus nivolumab as the last treatment
  • Brain metastases or leptomeningeal disease with symptoms
  • Taking more than 10mg oral prednisone or its equivalent
  • Taking an investigational drug
  • Pregnant women

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Adult patients (age > 18) with unresectable melanoma who have progressed on immune checkpoint inhibitor therapy (pembrolizumab, nivolumab, nivolumab-relatimab, atezolizumab, ipilimumab) and for whom their treating physician plans to initiate dual ICI with ipilimumab and nivolumab. Progression on adjuvant PD-1 inhibition is permitted. PD-1 does not have to be the last therapy received. This is no limited on prior lines of ICI received. There is no wash-out period required from the time of their last therapy
  • Patients are medically eligible for dual checkpoint inhibition (i.e. no untreated/uncontrolled intercurrent medical issue including ongoing immune-related adverse event or need for systemic steroids >10mg PO prednisone or its equivalent, ECOG PS ≤2) with ipilimumab 3mg/kg and nivolumab 1mg/kg by their treating physician
  • Must have a tumor amenable to percutaneous image-guided cryoablation based on routine Interventional Radiology criteria
  • Patients must have measurable disease (by RECIST) independent of the lesion to be ablated. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm with conventional techniques or as ≥10 mm with spiral CT scan, MRI, or calipers by clinical exam. See Section 11 (Measurement of Effect) for evaluation of measurable disease
  • Prior radiation therapy to any site is allowed; with an exception of the target site for planned cryoablation
  • ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A)
  • Life expectancy of greater than 3 months
  • Participants must have adequate organ and marrow function as defined below:; Leukocytes ≥3,000/mcL; Absolute neutrophil count ≥1,000/mcL; Platelets ≥75,000/mcL; Total bilirubin ≤3 institutional upper limit of normal (ULN); AST(SGOT)/ALT(SGPT) ≤5 × institutional ULN; CrCL > 30 ml/min
  • Known Human immunodeficiency virus (HIV)-infected participants on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. (HIV testing not required at screening)
  • For participants with known evidence of known chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. (HBV testing not required at screening)
  • Participants with a history of known hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load. (HCV testing not required at screening)
  • Participants with asymptomatic brain metastases are eligible
  • Participants with new or progressive asymptomatic brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy
  • Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
  • Ability to understand and the willingness to sign a written informed consent document

Who cannot take part

  • Lesion to undergo cryoablation cannot have had prior radiation therapy or other locoregional therapy
  • Inability to hold systemic anticoagulation prior to cryoablation (if holding anticoagulation is required by the operator)
  • Participants who are receiving an investigational agent(s)
  • Participants who are progressing on combination ipilimumab/nivolumab as their last line of therapy
  • Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1)
  • Pregnant women are excluded from this study because immune checkpoint inhibitors have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with immune checkpoint inhibitors, breastfeeding should be discontinued
  • Participants with uncontrolled intercurrent illness
  • Patients with symptomatic brain metastasis or LMD
  • Participants on > 10mg of oral prednisone or its equivalent

Where in United States

  • Massachusetts General Hospital Cancer CenterBoston, United StatesContact: Meghan J Mooradian, MDTaking people

About the trial

What the trial wants to find out

The aim of this study is to find out whether the combination of two approved drugs, ipilimumab and nivolumab, in combination with cryoablation are safe and effective for participants who have an unresectable melanoma that is resistant, or is growing, after receiving immunotherapy with a PD-1 inhibitor.

Read full original descriptionShow less

The names of the study interventions involved in this study are:

* Cryoablation (an interventional radiology procedure that freezes part of a tumor) * Ipilimumab (an immunotherapy) * Nivolumab (an immunotherapy)

The group in the trial

  • Ipilimumab + Nivolumab + CryoablationTreatment being tested

    Study will be conducted in two stages: Stage 1: Will enroll 15 participants, and if 6 or more have clinical benefit, the study will proceed to Stage 2. * Baseline CT scan. * Cycle 1-4: Pre-determined doses of ipilimumab and nivolumab. Medications administered under direction of treating oncologist. * Day 2 - 14: Core Needle Biopsy followed by cryoablation between Cycle 1 - 2 * Surveillance CT scan at weeks 8 - 12, weeks 16 - 24. * Follow up for 6 months to assess safety after cryoablation. Participants followed for duration of response. Stage 2: Will enroll 22 participants * Baseline CT scan. * Cycle 1-4: Pre-determined doses of ipilimumab and nivolumab. Medications administered under direction of treating oncologist. * Day 2- 14: Core Needle Biopsy followed by cryoablation between Cycle 1 - 2. * Surveillance CT scan at weeks 8 - 12, weeks 16 - 24 * Follow up period to assess safety 6 months after cryoablation. Patients followed for duration of response.

    Treatment: Ipilimumab, Nivolumab, and Cryoablation

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase II Study of Core Needle Biopsy and Cryoablation of an Enlarging Tumor in Patients With Advanced Melanoma Receiving Post-progression Dual Immune Checkpoint Inhibitor Therapy
Plain-language title
Freezing Tumors and Immunotherapy Drugs for Advanced MelanomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
27 August 2026